Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
29.01
-1.37 (-4.51%)
At close: Mar 30, 2026, 4:00 PM EDT
29.01
0.00 (0.00%)
After-hours: Mar 30, 2026, 7:02 PM EDT
Maze Therapeutics Employees
Maze Therapeutics had 141 employees as of December 31, 2025. The number of employees increased by 16 or 12.80% compared to the previous year.
Employees
141
Change (1Y)
16
Growth (1Y)
12.80%
Revenue / Employee
n/a
Profits / Employee
-$929,929
Market Cap
1.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 141 | 16 | 12.80% |
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 298 |
| Nanobiotix | 103 |
| Oculis Holding AG | 49 |
| Trevi Therapeutics | 34 |
MAZE News
- 3 days ago - Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop - Seeking Alpha
- 4 days ago - MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 5 days ago - Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Benzinga
- 5 days ago - Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease - GlobeNewsWire
- 5 days ago - Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 4 weeks ago - Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Maze Therapeutics: An Innovative, Nature-Driven Platform - Seeking Alpha